National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Catumazomab (Removab®) for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.

Rapid Review

Commenced Completed Outcome
05/08/2011 06/09/2011 Full Pharmacoeconomic Evaluation not Recommended.